This article provides a brief overview of the technical and conceptual advantages of Raman spectroscopy, a label-free imaging technique that is being increasingly used for the purpose of drug evaluation.
List view / Grid view
Taylor B Guo, Chief Scientific Officer at I-Mab, describes the potential benefits of bispecific antibodies for cancer therapy and how their dual targeting mechanisms of action may drive their emergence as the next generation of immuno-oncology drugs.
In this article, Aparajita Dubey discusses the role of antibodies in regulating the immune system and highlights key features that need to be considered for drug development and how this can be applied to cancer therapy.
In 2019, the SARS-CoV-2 coronavirus sparked a global pandemic that is likely to continue into 2021. Effective therapeutics that treat the symptoms of the disease and prevent or treat the underlying viral infection are critically required. To meet this need, the global biopharmaceutical industry is evaluating over 50 monoclonal antibody…
Adeno-associated virus (AAV)-mediated gene therapies allow for the treatment of a growing number of diseases; however, the presence of neutralising antibodies can lead to limitations of this technology, particularly for patients who may be excluded due to these pre-existing or developing neutralising antibodies. Recently, a study was published in Nature…
Expert view: Analytical power tool opens upstream bioprocessing bottlenecks for better antibody screening
The Octet® systems provide broad applications in high throughput to help bispecific and multi-specific antibody discovery.
Application note: Validated quantitation and activity assay of antibody fragment molecule (Fab) for process development and quality control
This application note by ForteBio explores antibody fragment molecule (Fab) for process development and quality control.
The high-throughput screening (HTS) facility at the Francis Crick Institute in the UK provides a core service for Crick research groups. It enables scientists to use large-scale, unbiased screening technologies and approaches as part of their research. Nikki Withers spoke to the Science Technology Platform Head, Michael Howell, to hear…
High-throughput screening is a common method of identifying lead compounds for drug development. The most common targets are enzymes – catalytic proteins that perform chemical reactions in the cell. In this article, Matthew Lloyd discusses the opportunities and challenges associated with this approach.
Exploring large databases and selecting compounds of interest can be extremely time-consuming for researchers. Here, Sacha Javor, Horst Flotow and Jingwen Shi discuss a novel chemoinformatics approach for drug discovery.
Current state of NAFLD treatments and the promise of in vitro platforms towards better screening of drug candidates
The heterogeneous pathogenesis of metabolic fatty liver diseases presents researchers with numerous challenges when trying to develop a treatment. This article explores the spectrum of these diseases and presents a novel in vitro platform for screening drug candidates.
Combine titer and glycan screening during clone selection and cell culture optimisation to make more informed choices sooner, significantly reducing the development time for therapeutic antibodies.
Application note: High-throughput sialylation screening in combination with titer monitoring for expediting clone selection in cell-line development
Glycosylation is one of the most important post-translational modifications when developing new biologics. It has a considerable impact on product performance and variability and is therefore a critical quality attribute (CQA), influencing product safety and efficacy.
Included in this in-depth focus are articles on how high-throughput screening can be used to identify lead compounds, using chemoinformatics as a map to guide drug discovery and a novel in vitro model to screen potential treatments for non-alcoholic fatty liver disease (NAFLD).